ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares saw strong trading volume on Monday . 228,885 shares were traded during trading, an increase of 5% from the previous session’s volume of 218,944 shares.The stock last traded at $55.40 and had previously closed at $54.91.

A number of analysts recently commented on the company. Zacks Investment Research raised ANI Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $55.00 price objective on the stock in a research note on Tuesday, April 26th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of ANI Pharmaceuticals in a research note on Tuesday, May 3rd. Guggenheim reissued a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of ANI Pharmaceuticals in a research note on Saturday, May 7th. Raymond James Financial Inc. assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 price target on the stock. Finally, Standpoint Research lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th. Four equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $55.88.

The company has a 50-day moving average price of $55.03 and a 200-day moving average price of $42.63. The stock has a market cap of $643.72 million and a P/E ratio of 52.64.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, May 5th. The specialty pharmaceutical company reported $0.76 EPS for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.12. The firm earned $20.60 million during the quarter, compared to the consensus estimate of $21.03 million. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 EPS. Analysts anticipate that ANI Pharmaceuticals Inc. will post $3.67 earnings per share for the current year.

Several large investors recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. GSA Capital Partners LLP now owns 55,447 shares of the specialty pharmaceutical company’s stock worth $2,502,000 after buying an additional 5,420 shares during the period. Deere & Co. bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth about $1,961,000. Finally, Mutual of America Capital Management LLC raised its stake in shares of ANI Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 30,178 shares of the specialty pharmaceutical company’s stock worth $1,362,000 after buying an additional 178 shares during the period.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.